EVH Evolent Health Inc - Ordinary Shares - Class A

$EVH Congratulations to us all! But it really is fascinating and impressive just how blatantly this share is being manipulated and driven down. Before the last earnings, the share is put on the watch list and the price plummets. Then, after the earnings, it creeps slowly over 3.5 weeks to $5. Then the share price crashes catastrophically, almost back to where it was before the earnings, on the grounds that interest rates are too high and, as the company has so much debt, high interest rates are a nightmare. Now, with no news whatsoever, the share price is soaring in 10 days!!! Back to $5 – why? Because the earnings weren’t rubbish last time either. Suddenly, interest rates don’t matter; suddenly, when the short-sellers let go of the button, the share price takes off. Fundamentally, nothing has changed and interest rates are higher than ever. I’ve never seen the share price rise so quickly. I reckon it’ll keep rising, but I wouldn’t be surprised by a correction but not to 3 back this time.

$EVH Potential catalyst from Trump’s new Executive Order on Women’s Health (Oct 19) 📊 The Quick Take: President Trump established a new NIH division & White House Task Force to accelerate research into complex/chronic conditions affecting women (oncology, autoimmune, etc.). Why it matters for EVH: • Specialty Care Alignment: EVH is a leader in value-based specialty care management. Better data/pathways in high-cost chronic areas directly enhance their clinical software & care models. • Government Contracts: New quality metrics/mandates for Medicaid/Medicare could force payers to optimize women's health outcomes—a core service EVH sells to insurers. • Sentiment: Long-term tailwind. Not an instant revenue spike, but lines up perfectly with their growth vectors. Stock already showing a positive response today. 📈

$EVH all major moving averages have been curling up. Once we break about 5 we should see 8 sooner than later

$EVH 10$ without q2 2027! 20$ if the company will show strong increase of revenues for 2027/8

$EVH Even 8 would be still undervalued. I am aiming now at 20s, in hope the upwards trends brings new instutionals and maybe even a buyout/M&A option back on the table